IMAC Stock Forecast, Price & News

+0.01 (+0.63 %)
(As of 08/2/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,854 shs
Average Volume418,499 shs
Market Capitalization$40.32 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

IMAC logo

About IMAC

IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. Its services include medical treatments, regenerative medicine, physical medicine, physical therapy, spinal decompression and chiropractic manipulation. The company was founded by Matthew C. Wallis, Jason William Brame and Jeffrey S. Ervin in August 2000 and is headquartered in Brentwood, TN.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.65 out of 5 stars

Medical Sector

1005th out of 2,221 stocks

Specialty Outpatient Clinics, Not Elsewhere Classified Industry

3rd out of 8 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

IMAC (NASDAQ:IMAC) Frequently Asked Questions

Is IMAC a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMAC stock.
View analyst ratings for IMAC
or view top-rated stocks.

What stocks does MarketBeat like better than IMAC?

Wall Street analysts have given IMAC a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IMAC wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting IMAC?

IMAC saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 117,700 shares, a decline of 20.1% from the June 30th total of 147,300 shares. Based on an average daily trading volume, of 401,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the shares of the stock are sold short.
View IMAC's Short Interest

When is IMAC's next earnings date?

IMAC is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for IMAC

How were IMAC's earnings last quarter?

IMAC Holdings, Inc. (NASDAQ:IMAC) posted its earnings results on Thursday, May, 13th. The company reported ($0.15) EPS for the quarter, hitting analysts' consensus estimates of ($0.15). The business had revenue of $3.06 million for the quarter, compared to analyst estimates of $3.53 million. IMAC had a negative trailing twelve-month return on equity of 56.26% and a negative net margin of 41.83%.
View IMAC's earnings history

How has IMAC's stock been impacted by COVID-19 (Coronavirus)?

IMAC's stock was trading at $0.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IMAC shares have increased by 95.1% and is now trading at $1.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IMAC?

1 Wall Street analysts have issued twelve-month price targets for IMAC's shares. Their forecasts range from $2.35 to $2.35. On average, they anticipate IMAC's share price to reach $2.35 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price.
View analysts' price targets for IMAC
or view top-rated stocks among Wall Street analysts.

Who are IMAC's key executives?

IMAC's management team includes the following people:
  • Jeffrey S. Ervin, Chairman & Chief Executive Officer
  • Matthew C. Wallis, Chief Operating Officer & Director
  • Sheri Gardzina, Secretary, Chief Financial & Accounting Officer

Who are some of IMAC's key competitors?

What other stocks do shareholders of IMAC own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMAC investors own include VBI Vaccines (VBIV), Biocept (BIOC), Energy Transfer (ET), iBio (IBIO), McEwen Mining (MUX), OPKO Health (OPK), Advanced Micro Devices (AMD), Amarin (AMRN), Aytu Biopharma (AYTU) and Bionano Genomics (BNGO).

When did IMAC IPO?

(IMAC) raised $4 million in an initial public offering (IPO) on the week of February 11th 2019. The company issued 900,000 shares at a price of $5.00 per share. Dawson James Securities and Cuttone acted as the underwriters for the IPO.

What is IMAC's stock symbol?

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

How do I buy shares of IMAC?

Shares of IMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IMAC's stock price today?

One share of IMAC stock can currently be purchased for approximately $1.60.

How much money does IMAC make?

IMAC has a market capitalization of $40.32 million and generates $12.84 million in revenue each year. The company earns $-5,000,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does IMAC have?

IMAC employs 147,000 workers across the globe.

What is IMAC's official website?

The official website for IMAC is

Where are IMAC's headquarters?

IMAC is headquartered at 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027.

How can I contact IMAC?

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company can be reached via phone at (844) 266-4622 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.